hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06315348 id: URI_116301123 briefTitle: Effect on Periodontal Phenotype of Flapless Piezoincission During Orthodontic Treatment acronym: Piezo_Ortho overallStatus: RECRUITING date: 2024-04 date: 2025-04 date: 2025-04 date: 2024-03-18 date: 2024-03-21 name: Universidad Complutense de Madrid class: OTHER name: Osteology Foundation briefSummary: Research Question
The aim of this randomized clinical trial (RCT) is to compare piezocision-assisted orthodontics, concomitant to soft tissue grafting (volume-stable collagen matrix), with piezocision-assisted orthodontics, concomitant to bone grafting with a xenograft and a native collagen membrane, in orthodontic non-growing patients. The primary aim will be to determine the impact of this surgical protocol on the hard and soft tissue changes occurring on the buccal aspect of the dentition. Secondary objectives will include the assessment of the comparative impact on treatment duration, rate of tooth movements, presence of root resorption, periodontal parameters, bone level changes and patient-reported outcome measures (PROMs) between the two groups. conditions: Dental Malocclusion conditions: Maxillary Deficiency studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Comparative 2-arm parallel double-blinded randomized controlled clinical trial primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Blinded parties will not be aware of the type augmentation used during the intervention. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: flapless alveolar decortication with augmentation measure: Soft tissue contour changes pre- and post- orthodontic therapy measure: Plaque index (PlI) measure: Bleeding on probbing (BoP) measure: Probing depth (PD) measure: External apical root resorption (EARR) measure: Orthodontic tooth movement measure: Percentage of residual pockets (PD>4 mm). measure: Soft tissue thickness by PIROP ultrasound scanner measure: Gingival microvasculature measure: PROMs measure: Adverse events (AEs) sex: ALL minimumAge: 16 Years maximumAge: 70 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Odontology, University Complutense Madrid status: RECRUITING city: Madrid zip: 28040 country: Spain name: Eduardo Montero, Prof role: CONTACT phone: +34 91 3941901 email: eduardomonterosolis@ucm.es name: Conchita Martin, Prof role: CONTACT phone: +34 91 3941901 email: mariacom@ucm.es lat: 40.4165 lon: -3.70256 hasResults: False
nctId: NCT06315335 id: UP0118 briefTitle: A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2025-07-29 date: 2025-07-29 date: 2024-03-18 date: 2024-04-16 name: UCB Biopharma SRL class: INDUSTRY briefSummary: The purpose of the study is investigate the safety, tolerability and pharmacokinetic of UCB9741 after 2 dose strengths administered subcutaneous as a single-dose in healthy Caucasian and Japanese participants. conditions: Healthy Participants studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 50 type: ESTIMATED name: UCB9741 name: Placebo measure: Occurrence of TEAEs measure: Occurrence of treatment-emergent SAEs measure: Cmax measure: AUC0-t measure: AUCinf sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06315322 id: EP0224 id: 2023-508095-11-00 type: REGISTRY domain: EU Trial Number id: U1111-1303-1174 type: OTHER domain: Universal Trial Number briefTitle: A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2029-02-28 date: 2029-02-28 date: 2024-03-18 date: 2024-03-18 name: UCB Biopharma SRL class: INDUSTRY briefSummary: The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy. conditions: Childhood Absence Epilepsy conditions: Juvenile Absence Epilepsy studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: Brivaracetam Film-coated tablet name: Brivaracetam oral solution measure: Incidence of treatment-emergent adverse events (TEAEs) during the study measure: Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of investigational medicinal product (IMP) during the study measure: Incidence of serious adverse events (SAEs) during the study measure: Incidence of IMP related TEAEs during the study sex: ALL minimumAge: 2 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06315309 id: IRB-300012281 (UAB 23146) briefTitle: Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant overallStatus: NOT_YET_RECRUITING date: 2024-06-29 date: 2025-10-29 date: 2027-02 date: 2024-03-18 date: 2024-04-03 name: University of Alabama at Birmingham class: OTHER briefSummary: The purpose of this study is to test whether the combination of the drugs called tacrolimus (Tac), methotrexate (MTX) and new dosing strategy of another drug called (rabbit Anti-thymocyte Globulin \[ATG\]) will help prevent the development and/or improve severity of acute and/or chronic GVHD. conditions: GVHD,Acute conditions: Acute Leukemia conditions: Myelodysplastic Syndromes conditions: Myeloproliferative Disorders studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 29 type: ESTIMATED name: ATG Combined with Tacrolimus and Mini Methotrexate measure: To estimate the therapeutic success of 2-step ATG dosing platform in patients undergoing reduced intensity allogeneic transplantation for treatment of hematologic malignances sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: University of Alabama at Birmingham city: Birmingham state: Alabama zip: 35294 country: United States name: Zaid S Al Kadhimi, MD role: PRINCIPAL_INVESTIGATOR name: Manuel Espinoza-Gutarra, MD role: SUB_INVESTIGATOR name: Omer Jamy, MD role: SUB_INVESTIGATOR name: Donna Salzman, MD role: SUB_INVESTIGATOR name: Razan Mohty, MD role: SUB_INVESTIGATOR name: Lauren Shea, MD role: SUB_INVESTIGATOR lat: 33.52066 lon: -86.80249 hasResults: False
nctId: NCT06315283 id: TV44749-BA-10196 id: 2023-505664-11-00 type: REGISTRY domain: CTIS briefTitle: An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia overallStatus: RECRUITING date: 2024-03-20 date: 2025-04-15 date: 2025-04-15 date: 2024-03-18 date: 2024-04-22 name: Teva Branded Pharmaceutical Products R&D, Inc. class: INDUSTRY briefSummary: The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia.
The total duration of participation in the trial for each participant is planned to be approximately 21 weeks. conditions: Schizophrenia studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 116 type: ESTIMATED name: TV-44749 name: Oral olanzapine measure: Area under the curve (AUC) of TV-44749 measure: AUC of oral olanzapine measure: Number of participants with at least one treatment-emergent adverse event during treatment with TV-44749 measure: Number of participants with at least one treatment-emergent serious adverse event during treatment with TV-44749 measure: Number of participants with at least one injection site adverse event during treatment with TV-44749 measure: Maximum observed plasma drug concentration at steady state (Cmax,ss) of TV-44749 measure: Minimum observed plasma drug concentration at steady state (Cmin,ss) of TV-44749 measure: Cmax,ss of oral olanzapine measure: Cmin,ss of oral olanzapine sex: ALL minimumAge: 18 Years maximumAge: 64 Years stdAges: ADULT facility: Teva Investigational Site 15739 status: RECRUITING city: Los Alamitos state: California zip: 90720 country: United States lat: 33.80307 lon: -118.07256 facility: Teva Investigational Site 15740 status: RECRUITING city: Torrance state: California zip: 90504 country: United States lat: 33.83585 lon: -118.34063 facility: Teva Investigational Site 15738 status: RECRUITING city: Hollywood state: Florida zip: 33024 country: United States lat: 26.0112 lon: -80.14949 facility: Teva Investigational Site 15741 status: RECRUITING city: Atlanta state: Georgia zip: 30308 country: United States lat: 33.749 lon: -84.38798 facility: Teva Investigational Site 15742 status: RECRUITING city: Decatur state: Georgia zip: 30030 country: United States lat: 33.77483 lon: -84.29631 facility: Teva Investigational Site 15737 status: RECRUITING city: Marlton state: New Jersey zip: 08053 country: United States lat: 39.89122 lon: -74.92183 hasResults: False
nctId: NCT06315270 id: 24K040-001 briefTitle: To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer overallStatus: NOT_YET_RECRUITING date: 2024-03-20 date: 2029-03-20 date: 2029-03-20 date: 2024-03-18 date: 2024-04-01 name: The First Hospital of Jilin University class: OTHER briefSummary: This project proposes to elucidate the functional impact of T cells in cancer progression and treatment through a comprehensive TCR profiling study and a longitudinal cohort study in patients with advanced epithelial ovarian cancer. Our findings aim to provide clinical insights for monitoring treatment response in a non-invasive way and demonstrate the association of TCR diversity with clinical outcomes and the potential role of TCR profiling in cancer prognosis. conditions: Epithelial Ovarian Cancer conditions: Stage III Ovarian Cancer conditions: Stage IV Ovarian Cancer studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 100 type: ESTIMATED measure: Analysis of TCR genealogy data sex: FEMALE minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06315257 id: J23105sIRB id: IRB00388854 type: OTHER domain: Johns Hopkins briefTitle: A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2026-08 date: 2027-03 date: 2024-03-18 date: 2024-03-18 name: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins class: OTHER name: National Institutes of Health (NIH) briefSummary: A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy. conditions: Cervical Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 32 type: ESTIMATED name: PVX7 measure: Safety of PVX7 as assessed by adverse events measure: Feasibility of PVX7 measure: Cellular Immune Response measure: Immune Response measure: Presence of circulating HPV DNA sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06315244 id: 2558 briefTitle: Perforating Cutaneous Nerve Injection Efficacy in Chronic Coccydynia: A Randomized, Double-Blind Study overallStatus: RECRUITING date: 2024-04-01 date: 2024-07-01 date: 2024-10-01 date: 2024-03-18 date: 2024-03-18 name: Sisli Hamidiye Etfal Training and Research Hospital class: OTHER briefSummary: Interventions targeting the perforating cutaneous nerve are relatively new to the literature, with a safe side-effect profile but lacking high-quality studies. Their effectiveness remains at the level of case presentations. According to the hypothesis expressed in these publications, coccydynia might be an overlooked cause due to the compression of the perforating cutaneous nerve where it pierces the sacrotuberous ligament and becomes superficial. Ultimately, it is hypothesized that injection of dextrose into this ligament and the sensory area of this nerve will resolve these symptoms due to nerve entrapment, similar to other entrapment neuropathies treated with 5% dextrose, like carpal tunnel syndrome. conditions: Coccyx Disorder conditions: Coccyx Injury studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: US Guided Perineural Injection and Neuroprolotherapy measure: Effectiveness of Perforating Cutaneous Nerve Injection measure: Change in Pressure Pain Threshold measure: Change in Quality of Life sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Sisli Hamidiye Etfal Training and Research Hospital status: RECRUITING city: Istanbul zip: 34371 country: Turkey name: Enes Efe Is, MD role: CONTACT phone: +902123735000 email: enefeis@gmail.com name: Enes Efe Is, MD role: PRINCIPAL_INVESTIGATOR lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06315231 id: SIM0308-02-Y-2-201 briefTitle: Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients overallStatus: NOT_YET_RECRUITING date: 2024-03-31 date: 2024-12-31 date: 2025-05-30 date: 2024-03-18 date: 2024-03-18 name: Simcere Pharmaceutical Co., Ltd class: OTHER briefSummary: This is a multicenter, randomized, double-blind, placebo-controlled, exploratory Phase II clinical trial.
Participants will be required to receive 12 weeks treatment of edaravone dexborneol sublingual tablets or placebo during this study. The safety and efficacy endpoints will be compared in the patients with edaravone dexborneol sublingual tablets or placebo. conditions: Post-stroke Cognitive Impairment studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Edaravone dexborneol sublingual tablet name: Placebo measure: Adverse Events measure: Number of discontinuation/withdrawal patients measure: The changes of the Vascular Dementia Assessment Scale-cognitive subscale (VaDAS-Cog) scores. measure: The incidence of Post Stroke Cognitive Impairment（PSCI ）in each group measure: The changes of Mini-Mental State Examination (MMSE) score measure: The changes of Montreal Cognitive Assessment (MoCA) scale measure: The changes of MoCA subscales measure: Modified Rankin Scale (mRS) scores measure: The changes of National Institutes of Health Stroke Scale sex: ALL minimumAge: 40 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of USTC Anhui Provincial Hospital city: Hefei state: Anhui country: China name: Jiong Shi, Doctor role: CONTACT email: Jshi2022@ustc.edu.cn lat: 31.86389 lon: 117.28083 facility: The First Hospital of Jilin University city: Changchun state: Jilin country: China name: Li Sun role: CONTACT email: sunli99@jlu.edu.cn lat: 43.88 lon: 125.32278 facility: The First People's Hospital of Huzhou city: Huzhou state: Zhejiang country: China name: Ru Sun, Doctor role: CONTACT email: sunjin2010@tom.com lat: 30.8703 lon: 120.0933 hasResults: False
nctId: NCT06315218 id: Pro2023000968 briefTitle: Examining the Health Effects of iTHRIVE 365 Among Black Same Gender Loving Men overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2028-04 date: 2028-04 date: 2024-03-18 date: 2024-03-21 name: Rutgers, The State University of New Jersey class: OTHER name: Positive Impact Health Centers name: George Washington University name: Carnegie Mellon University name: Emory University name: Columbia University name: Arizona State University name: THRIVE Social Services Inc briefSummary: This research study aims to test the effectiveness, reach, and maintenance over time of the iTHRIVE 365 intervention for Black same gender loving men (SGLM) living with HIV. iTHRIVE 365 is a SGLM community-developed multicomponent mHealth intervention that aims to: 1) Support daily health promotion via HIV and psychological health education and health maintenance reminders; 2) Foster positive social connections among SGLM via online moderated forums, interpersonal chats, and community calendars; 3) Connect clients to SGLM-affirming healthcare, including HIV treatment and mental healthcare; 4) Provide resources for housing, transportation, and other economic empowerment. conditions: Sexual and Gender Minorities conditions: Social Stigma conditions: Medication Adherence conditions: Depressive Symptoms conditions: Anxiety Symptoms studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 350 type: ESTIMATED name: iTHRIVE 365 HIV care intervention measure: Antiretroviral (ART) Medication Use measure: ART adherence-Long Lag Assessments measure: Daily Diary Substance Use measure: Substance Use-Long Lag Assessments measure: Depressive Symptoms measure: Depressive Symptoms-Long Lag measure: Anxiety Symptoms measure: Anxiety Symptoms-Long Lag measure: Emotion Regulation Emotion Regulation measure: Emotion Regulation-Long Lag Assessments measure: COPE measure: COPE-Long Lag Assessments sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06315205 id: ROV-LEBE-2023-01 id: 2023-503948-13 type: EUDRACT_NUMBER briefTitle: Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women acronym: LEILA-1 overallStatus: RECRUITING date: 2023-07-26 date: 2025-01 date: 2025-01 date: 2024-03-18 date: 2024-03-19 name: Rovi Pharmaceuticals Laboratories class: INDUSTRY briefSummary: This is a Phase I, open label, sequential, single ascending dose (SAD) study to evaluate the pharmacokinetic (PK), safety, and tolerability of Letrozole LEBE in healthy post-menopausal women. conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 90 type: ESTIMATED name: Letrozole LEBE 75 mg name: Letrozole LEBE 150 mg name: Letrozole LEBE 225 mg measure: λz measure: Cmax measure: Clast measure: tmax measure: tlag measure: t1/2 measure: AUC∞ measure: AUClast measure: E1 measure: SE1 measure: E2 measure: λz measure: Cav measure: Cmin, ss measure: Cmax,ss measure: tmax measure: t1/2 measure: AUCτ sex: FEMALE minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Investigational Site number CZ-01 status: RECRUITING city: Praha country: Czechia lat: 50.08804 lon: 14.42076 hasResults: False
nctId: NCT06315192 id: CIV-22-10-041006 briefTitle: Stroke Alarm Efficacy Trial acronym: StrokeAlarmEFF overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-12-31 date: 2026-06-30 date: 2024-03-18 date: 2024-03-18 name: Region Skane class: OTHER briefSummary: The aim of this study is to test the efficacy of the CE-marked wearable system Stroke Alarm to identify the onset of a stroke with unilateral arm motor deficit within 3 hours of onset.
The combined efficacy goal is at least 60% sensitivity for Stroke Alarm b of stroke with unilateral arm motor deficit within 3 hours of onset (with a 95% confidence interval above 30%) and a specificity of at least 80% using a clinical stroke diagnosis as gold standard. conditions: Stroke Acute conditions: Atrial Fibrillation conditions: TIA studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a multicenter, prospective observational single-arm trial with a registry-based propensity matched control population. primaryPurpose: DIAGNOSTIC masking: NONE count: 500 type: ESTIMATED name: Stroke Alarm measure: Time from onset of stroke with unilateral arm motor deficit until alarm by the device. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Skane University hospital city: Lund zip: 22185 country: Sweden name: Johan Wasselius, MD, PhD role: CONTACT phone: 800-555-5555 phoneExt: +46-46173082 email: johan.wasselius@gmail.com name: Magnus Esbjörnsson, MD role: PRINCIPAL_INVESTIGATOR lat: 55.70584 lon: 13.19321 hasResults: False
nctId: NCT06315179 id: STUDY00004616 briefTitle: Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE) acronym: STRIDE overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2028-01 date: 2030-01 date: 2024-03-18 date: 2024-03-19 name: Seattle Children's Hospital class: OTHER name: Allen Institute briefSummary: This is a prospective observational study collecting long-term clinical data and samples for research in pediatric inflammatory bowel disease (IBD) patients with gut inflammation and a control cohort of pediatric patients with disorders of the brain-gut interactions (DBGI) with no detectable gut inflammation. conditions: Inflammatory Bowel Diseases conditions: Crohn Disease conditions: Ulcerative Colitis conditions: Indeterminate Colitis conditions: Functional Abdominal Pain Syndrome conditions: Functional Bowel Disorder conditions: Esophageal Diseases conditions: Gastroduodenal Disorder conditions: Bowel Dysfunction conditions: Gallbladder Diseases conditions: Sphincter of Oddi Dysfunction conditions: Anorectal Disorder studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Esophagogastroduodenoscopy (EGD) with biopsy name: Colonoscopy w/ biopsy measure: Bio-repository sample collection for spatial transcriptomics measure: Paris Classification of Crohn's Disease measure: Montreal Classification of Crohn's disease measure: Paris Classification of Ulcerative Colitis/Indeterminate Colitis measure: Montreal Classification of Ulcerative Colitis/Indeterminate Colitis measure: Disorder of Gut-Brain Interaction classification measure: Physician's Global Assessment (PGA) sex: ALL minimumAge: 6 Years maximumAge: 21 Years stdAges: CHILD stdAges: ADULT facility: Seattle Children's Hospital city: Seattle state: Washington zip: 98105 country: United States name: Mason E Nuding role: CONTACT phone: 206-987-0055 email: mason.nuding@seattlechildrens.org name: Clinical Research Coordinator role: CONTACT phone: 206-987-2521 email: giresearch@seattlechidlrens.org name: Hengqi Zheng, MD role: PRINCIPAL_INVESTIGATOR lat: 47.60621 lon: -122.33207 hasResults: False
nctId: NCT06315166 id: CIP-PLG_CLINICAL-22-04 briefTitle: Study on Using Radiofrequency to Treat Moderate to Severe Acne overallStatus: RECRUITING date: 2024-04-10 date: 2025-09 date: 2025-12 date: 2024-03-18 date: 2024-04-11 name: Pollogen class: INDUSTRY name: Lumenis Be Ltd. briefSummary: Evaluation of the safety and efficacy of fractional radiofrequency for the treatment of moderate to severe acne vulgaris. conditions: Moderate to Severe Acne Vulgaris studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: triLift/Legend Pro+ Fractional RF System measure: Evaluate the Efficacy of Fractional RF for the Treatment of Moderate to Severe Acne Vulgaris measure: Overall Improvement of Acne measure: Subjective Satisfaction with the Treatment Results sex: ALL minimumAge: 18 Years maximumAge: 25 Years stdAges: ADULT facility: Cosmedic Dermatology (CosmedicDerm) status: RECRUITING city: Grosse Pointe state: Michigan zip: 48230 country: United States name: Shauna Ryder Diggs, MD role: CONTACT phone: 313-882-5777 email: hello@drshaunadiggs.com name: Jamila Ammary role: CONTACT phone: +1-313-882-5777 email: hello@drshaunadiggs.com name: Shauna Ryder Diggs, MD role: PRINCIPAL_INVESTIGATOR lat: 42.38615 lon: -82.91186 hasResults: False